![]() | |
Clinical data | |
---|---|
Other names | TAK-063; TAK063 |
Drug class | Phosphodiesterase inhibitor; PDE10A inhibitor; Antipsychotic |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H17FN6O2 |
Molar mass | 428.427 g·mol−1 |
3D model (JSmol) | |
| |
|
Balipodect (INN , USAN ; developmental code name TAK-063) is a selective phosphodiesterase 10A (PDE10A) inhibitor which was under development by Takeda for the treatment of schizophrenia. [1] [2] [3]
It is active in animal models of antipsychotic-like activity, including inhibition of hyperlocomotion induced by the NMDA receptor antagonist dizocilpine (MK-801) or the dopamine releasing agent methamphetamine, inhibition of conditioned avoidance responses, and reversal of prepulse inhibition deficits. [4]
The drug reached phase 2 clinical trials for this indication but its development was discontinued. [1] [2] It was reported to be poorly effective or ineffective for schizophrenia in clinical trials. [5] [6] [7]